SCHEMBL24329676

SCHEMBL24329676

Cn1ccc(C(=O)Nc2nc(-c3ccc(NC(=O)c4ccccn4)cc3)cs2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.53
▸ NPC1 O15118 3/20 0.53
▸ RAB9A P51151 3/20 0.53
▸ MAPK1 P28482 3/20 0.53
▸ LMNA P02545 5/20 0.53
▸ ROCK1 Q13464 3/20 0.52
▸ MEN1 O00255 8/20 0.51
▸ KMT2A Q03164 8/20 0.51
▸ ALDH1A1 P00352 5/20 0.51
▸ HTT P42858 5/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ KDM4E B2RXH2 2/20 0.51
▸ TP53 P04637 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ HPGD P15428 1/20 0.51
▸ TSHR P16473 1/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ HSD17B10 Q99714 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ MITF O75030 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24329677 0.86 L3MBTL1 (0.67) MAPTNPC1RAB9AMAPK1LMNA
SCHEMBL24330744 0.85 PARP1 (0.57) MAPTLMNAROCK1MEN1KMT2A
SCHEMBL26658235 0.84 LMNA (0.59) MAPTNPC1RAB9AMAPK1LMNA
SCHEMBL26884172 0.83 MEN1 (0.54) MAPTNPC1RAB9ALMNAROCK1
SCHEMBL26884180 0.83 KMT2A (0.61) MAPTNPC1RAB9AMAPK1LMNA
SCHEMBL24329679 0.81 MEN1 (0.62) MAPTNPC1RAB9AMAPK1LMNA
SCHEMBL12248896 0.80 ADORA3 (0.68) MAPTNPC1RAB9AMAPK1LMNA
SCHEMBL15400878 0.80 LMNA (0.73) MAPTNPC1RAB9AMAPK1LMNA
SCHEMBL12249049 0.79 LMNA (0.65) MAPTNPC1RAB9AMAPK1LMNA
SCHEMBL26884060 0.79 ADORA3 (0.70) MAPTNPC1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 — — US disclosed
WO-2022082071-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF US THEREOF CARTHRONIX, INC. (US) 2022-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF STAT1, STAT3, STAT6 MAPT 4065/4885NPC1 2133/4885RAB9A 3504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback